Announcement
15.09.2011

The World Congress on Huntington's disease is held every two years and attracts
a broad range of members from the Huntington's disease community, including
healthcare professionals, research scientists and industry representatives,
representatives from the major Huntington's disease organisations, as well as
patients and their caregivers. This year, the congress took place in Melbourne,
Australia, from 11-14 September and attracted more than 400 delegates from all
over the world.

Supported by NeuroSearch, University of Lyon, France, has initiated the Global
Huntington's Disease Burden study (GHDB), which is the first international
study of the socioeconomic burden of Huntington's disease. The following
notable findings were presented at the congress:

-- The direct medical costs (hospital visits, nursing home etc) associated
with Huntington's disease in France amount to appox. EUR 24,000 per patient
per year
-- The Huntington's Quality of Life Index (H-QoL-I) has been validated
cross-culturally with data from the United States, Germany, Poland, France
and Italy
-- A survey in Poland and Italy reported an average time spent by caregivers
caring for a patient of more than 20 hours/day
-- Among caregivers surveyed in the United States, 43% reported significant
deterioration of their quality of life

The unique data emerging from the GHDB study provide insights into the grave
consequences of Huntington's disease for patients, caregivers and society as a
whole. These consequences range from many hours of daily care to direct
expenses and loss of quality of life to significant productivity losses for
those affected by this devastating hereditary disease.

These data highlight the need for further research into Huntington's disease,
as well as the need to develop novel effective therapies.

"We are grateful for the support NeuroSearch provides in this project, which is
the first of its kind in Huntington's disease. We believe that the
international Huntington's disease community will be encouraged by the
information emerging from the study, which should help ensure that patients and
caregivers receive appropriate attention from healthcare policymakers and
politicians," commented Professor Mondher Toumi, University Claude Bernard Lyon
I.

The presentations can be found at the company's website via the following link:
http://neurosearch.com/Default.aspx?ID=8170&PID=47239&M=NewsV2&Action=1&NewsId=1
6099

Patrik Dahlen

CEO

Contact person:
René Schneider, EVP & CFO, telephone: +45 2911 2097

About NeuroSearch
NeuroSearch A/S is a European-based biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The company consists of two independent businesses. Specialty Pharma
is the company's specialty pharma business focused on completing the
development and marketing of Huntexil®, a unique drug in Phase III for the
treatment of the motor symptoms of Huntington's disease. NsDiscovery is
managing the company's early drug discovery and research, out-licensing of
product candidates targeting non-specialist indications, and the company's
partnerships. The company has strategic research and development alliances with
Janssen and Lilly as well as a licence agreement with Abbott.

Fonds.21-11 - NS in Melbourne - uk.pdf